Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

Nat Med. 2008 Jan;14(1):25-7. doi: 10.1038/nm1698. Epub 2007 Dec 6.


A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / chemistry
  • Epitopes / chemistry
  • Hepacivirus / metabolism*
  • Hepatitis Antibodies / chemistry*
  • Hepatitis C / prevention & control*
  • Hepatitis C / virology*
  • Humans
  • Immunoglobulin G / chemistry
  • Mice
  • Neutralization Tests
  • Rats
  • Species Specificity
  • Viral Hepatitis Vaccines


  • Antibodies, Monoclonal
  • Epitopes
  • Hepatitis Antibodies
  • Immunoglobulin G
  • Viral Hepatitis Vaccines